Extracellular is a contract development and manufacturing organization (CDMO) that specializes in biomanufacturing processes for cultivated meat and seafood, utilizing non-human cell culture technologies to produce biomass efficiently. The company addresses the challenge of scaling production in sustainable biotechnology by providing tailored cell culture media and large-scale bioreactor capabilities to accelerate time to market for its clients.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The cultivated meat and seafood industry faces significant challenges in scaling production from laboratory to commercial levels. Existing infrastructure often requires substantial capital expenditure and lengthy timelines, hindering companies from efficiently reaching the market.
Solution
Extracellular is a contract development and manufacturing organization (CDMO) that provides biomanufacturing services to accelerate the commercialization of cultivated meat, seafood, and other cell-cultivated products. The company offers tailored process development, media optimization, and scale-up capabilities, leveraging advanced bioprocessing techniques and equipment. Extracellular's pilot facility enables companies to bypass the need for building their own pilot plants, reducing capital expenditure and accelerating time to market. By offering expertise in cell-line development and access to license-free cell banks, Extracellular supports companies in achieving efficient and sustainable production of cell-cultivated products.
Target Audience
Extracellular serves cultivated meat and seafood companies, as well as other sustainable biotech companies utilizing non-human cell culture technologies, including plant cell culture foods, nutraceuticals, and cosmetic biotech companies.
Features
- Cell and media development using high-throughput screening and automation
- Bioreactor optimization with parallel bioreactor systems
- Scale-up capabilities from 1L to 2000L bioreactors
- Process development for both adherent and suspension cells, primary or pluripotent stem cells
- Food-grade pilot facility for contract manufacturing
- Support for animal component removal from media formulations
- Access to license-free cell banks